Peptides by Human-Data Status
A reader's filter for evidence-base maturity. Approved → known human-trial data → preclinical-only.
Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.
Human-data status is the single most useful filter for interpreting peptide claims. A peptide with human RCT data has been observed in people — not just in cell cultures or rodent models. A peptide with no human data has, by definition, an untested human safety and efficacy profile, regardless of how many in-vitro or animal papers are cited in its marketing. Approval status is a separate axis: a compound can have human trial data and an FDA label (tesamorelin: Egrifta SV, DailyMed set id 3d783378, and Egrifta WR, set id 839334d3, both effective 29 July 2026; bremelanotide: Vyleesi, set id f1d0c1b5, effective 13 November 2025) while the MHRA’s GLP-1 page (updated 5 February 2026) lists tirzepatide (Mounjaro) among licensed GLP-1 medicines. See human data vs preclinical data for the underlying distinction.
| Peptide | Human data | UK approval | Class | Grade | Main uncertainty |
|---|---|---|---|---|---|
| BPC-157 — Body Protection Compound 157 | limited | not-approved | Tissue Repair | C | Human clinical evidence is limited or not established; published evidence is mostly preclinical. |
| Cerebrolysin — Porcine-Brain Neuropeptide Preparation | limited | not-approved | Neuropeptide | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| CJC-1295 — GHRH(1-29) Analogue (no DAC / DAC variants) | limited | not-approved | GHRH Analogue | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| DSIP — Delta Sleep-Inducing Peptide | limited | not-approved | Neuropeptide | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| Epitalon — Pineal Tetrapeptide Bioregulator | limited | not-approved | Khavinson Bioregulator | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| GHK-Cu — Copper Tripeptide-1 | limited | not-approved | Tissue Repair | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| GHRP-2 — Growth Hormone Releasing Peptide 2 (Research Evidence Summary) | limited | not-approved | GH Secretagogue (GHRP) | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| Ipamorelin — Selective Growth Hormone Secretagogue | limited | not-approved | GH Secretagogue (GHRP) | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| Kisspeptin-10 — GnRH-Axis Hypothalamic Decapeptide | limited | not-approved | Kisspeptin Family | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| LL-37 — Human Cathelicidin Antimicrobial Peptide | limited | not-approved | Antimicrobial / Cathelicidin | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| Melanotan II — Broad-Spectrum α-MSH Analogue | limited | not-approved | Melanocortin | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| Pinealon — Pineal Tripeptide Bioregulator | limited | not-approved | Khavinson Bioregulator | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| Retatrutide — Triple GIP/GLP-1/Glucagon Receptor Agonist | limited | not-approved | Incretin (GLP-1 / GIP / Glucagon) | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| Selank — Tuftsin-Derivative Anxiolytic Heptapeptide | limited | not-approved | Neuropeptide | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| Semax — ACTH(4-10) Heptapeptide Nootropic | limited | not-approved | Neuropeptide | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| TB-500 — Thymosin β-4 Fragment (Ac-LKKTETQ) | limited | not-approved | Tissue Repair | C | Human clinical evidence is limited or not established; published evidence is mostly preclinical. |
| Thymalin — Thymic Peptide Complex Bioregulator | limited | not-approved | Thymic Peptide | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| Thymosin α-1 — Thymic Immunomodulatory Peptide (Zadaxin / Thymalfasin) | limited | not-approved | Thymic Peptide | B | Human trials exist; benefit beyond the people and conditions studied is not established. |
| AOD-9604 — Growth Hormone C-terminal Lipolytic Fragment | no | not-approved | GH Lipolytic Fragment | C | Human clinical evidence is limited or not established; published evidence is mostly preclinical. |
| Cagrilintide — Long-Acting Amylin Analogue (Research Evidence Summary) | no | not-approved | Incretin (GLP-1 / GIP / Glucagon) | C | Human clinical evidence is limited or not established; published evidence is mostly preclinical. |
| Humanin — Mitochondrial-Derived 24-Amino-Acid Peptide | no | not-approved | Mitochondrial Peptide | C | Human clinical evidence is limited or not established; published evidence is mostly preclinical. |
| KPV — α-MSH(11-13) C-Terminal Tripeptide | no | not-approved | Melanocortin | C | Human clinical evidence is limited or not established; published evidence is mostly preclinical. |
| MK-677 (Ibutamoren) — Oral Ghrelin-Receptor Agonist (Research Evidence Summary) | no | not-approved | GH Secretagogue (GHRP) | C | Human clinical evidence is limited or not established; published evidence is mostly preclinical. |
| MOTS-c — Mitochondrial Open Reading Frame 12S rRNA-c | no | not-approved | Mitochondrial Peptide | C | Human clinical evidence is limited or not established; published evidence is mostly preclinical. |
| PT-141 (Bremelanotide) — Melanocortin Receptor Agonist (Vyleesi) | yes | unclear | Melanocortin | B | FDA-approved as Vyleesi (bremelanotide; DailyMed label effective 13 November 2025) for premenopausal women with acquired, generalized hypoactive sexual desire disorder. No UK marketing authorisation found in an eMC search (3 November 2026); eMC is not a complete UK register. |
| Semaglutide — GLP-1 Receptor Agonist (Research Evidence Summary) | yes | approved | Incretin (GLP-1 / GIP / Glucagon) | A | Licensed in the UK as Wegovy, Ozempic and Rybelsus according to the MHRA (page updated 5 February 2026). Off-label or off-indication use is not within the licensed evidence base. |
| SS-31 (Elamipretide) — Cardiolipin-Targeted Mitochondrial Peptide | yes | unclear | Mitochondrial Peptide | B | FDA accelerated approval as Forzinity (elamipretide; DailyMed label effective 10 December 2025) to improve muscle strength in adult and paediatric patients with Barth syndrome who weigh at least 30 kg. No UK marketing authorisation found in an eMC search (3 November 2026); eMC is not a complete UK register. |
| Tesamorelin — Stabilised GHRH Analogue (EGRIFTA) | yes | unclear | GHRH Analogue | B | FDA-approved as Egrifta SV and Egrifta WR (DailyMed labels effective 29 July 2026) to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. No UK marketing authorisation found in an eMC search (3 November 2026); eMC is not a complete UK register. |
| Tirzepatide — Dual GIP/GLP-1 Receptor Agonist (Mounjaro / Zepbound) | yes | approved | Incretin (GLP-1 / GIP / Glucagon) | A | Licensed in the UK as Mounjaro according to the MHRA (page updated 5 February 2026). Off-label or off-indication use is not within the licensed evidence base. |
If you spot an error or have new evidence to suggest, please use our corrections policy.